Status:
COMPLETED
Andosan in Allergic and Asthma Patients
Lead Sponsor:
University Hospital, Akershus
Collaborating Sponsors:
Oslo University Hospital
ImmunoPharma AS
Conditions:
Allergic Asthma
Allergic Rhinoconjunctivitis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Examine whether daily oral ingestion of a immunomodulatory mushroom extract (AndoSanTM) in patients with asthma and allergy, undergoing allergen specific immunotherapy experience clinical and biochemi...
Detailed Description
Asthma and allergy are increasing in Norway and Western countries. Treatment is still mostly symptomatic. Extracts of the immunomodulatory and edible mushroom Agaricus blazei, such as Andosan™, have b...
Eligibility Criteria
Inclusion
- Asthma or allergy patients that are eligible for ASIT (Allergen specific immunotherapy).
- Age above 18.
- Able to understand written and oral Norwegian
Exclusion
- \- none other than not meeting the inclusion criteria
Key Trial Info
Start Date :
August 31 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 28 2023
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT05192720
Start Date
August 31 2021
End Date
February 28 2023
Last Update
June 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Akershus university hospital
Lørenskog, Akershus, Norway, 1478